NASDAQ:PAHC - Phibro Animal Health Stock Price, Forecast & News

Phibro Animal Health's stock was trading at $24.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PAHC shares have decreased by 17.6% and is now trading at $20.26. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 1 sell rating and 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Phibro Animal Health.

Phibro Animal Health is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Phibro Animal Health.

Phibro Animal Health Corp (NASDAQ:PAHC) posted its quarterly earnings data on Monday, February, 3rd. The company reported $0.34 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.06. The business earned $214 million during the quarter, compared to analyst estimates of $218.87 million. Phibro Animal Health had a net margin of 4.67% and a return on equity of 23.94%. The business's revenue was down 1.9% compared to the same quarter last year. During the same period last year, the firm earned $0.41 EPS. View Phibro Animal Health's earnings history.

Phibro Animal Health announced a quarterly dividend on Monday, February 3rd. Stockholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share on Wednesday, March 25th. This represents a $0.48 annualized dividend and a yield of 2.37%. The ex-dividend date is Tuesday, March 3rd. View Phibro Animal Health's dividend history.

Phibro Animal Health issued an update on its FY20 earnings guidance on Monday, February, 3rd. The company provided EPS guidance of $1.15-1.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.11. The company issued revenue guidance of $812-828 million, compared to the consensus revenue estimate of $838.36 million.

6 brokers have issued 12 month price objectives for Phibro Animal Health's shares. Their forecasts range from $18.00 to $30.00. On average, they anticipate Phibro Animal Health's share price to reach $25.20 in the next year. This suggests a possible upside of 24.4% from the stock's current price. View analysts' price targets for Phibro Animal Health.

Media coverage about PAHC stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Phibro Animal Health earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutPhibro Animal Health.

Phibro Animal Health saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 867,200 shares, an increase of 16.3% from the February 27th total of 745,900 shares. Based on an average daily volume of 197,400 shares, the days-to-cover ratio is presently 4.4 days. Currently, 4.3% of the company's stock are sold short. View Phibro Animal Health's Current Options Chain.

Some companies that are related to Phibro Animal Health include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Emergent Biosolutions (EBS), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), HUTCHISON CHINA/S (HCM), PTC Therapeutics (PTCT), Myokardia (MYOK), Deciphera Pharmaceuticals (DCPH) and Allakos (ALLK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Phibro Animal Health investors own include Zynga (ZNGA), Trevena (TRVN), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Sonoma Pharmaceuticals (SNOA), Zynerba Pharmaceuticals (ZYNE), Zoetis (ZTS), Booking (BKNG), Banco Bradesco (BBD) and Gilead Sciences (GILD).

Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."

Phibro Animal Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (2.68%), Principal Financial Group Inc. (2.35%), Renaissance Technologies LLC (2.07%), State Street Corp (1.71%), Cove Street Capital LLC (1.47%) and Eagle Asset Management Inc. (1.16%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, E Thomas Corcoran and Jack Bendheim. View institutional ownership trends for Phibro Animal Health.

PAHC stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Ceredex Value Advisors LLC, Nuveen Asset Management LLC, Acadian Asset Management LLC, Oxford Asset Management LLP, Bank of New York Mellon Corp, Goldman Sachs Group Inc., and AQR Capital Management LLC. View insider buying and selling activity for Phibro Animal Health.

PAHC stock was bought by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Eagle Asset Management Inc., Madison Asset Management LLC, Heartland Advisors Inc., Norges Bank, Martingale Asset Management L P, Raymond James & Associates, and Renaissance Technologies LLC. View insider buying and selling activity for Phibro Animal Health.

Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PAHC stock can currently be purchased for approximately $20.26.

Phibro Animal Health has a market capitalization of $819.52 million and generates $828 million in revenue each year. The company earns $54.71 million in net income (profit) each year or $1.53 on an earnings per share basis. Phibro Animal Health employs 1,600 workers across the globe. View additional information about Phibro Animal Health.

The official website for Phibro Animal Health is http://www.pahc.com/.

Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]